Anquan Ma, Chuanyao Zhai, Qixuan He, Wenhao Wang, Huiping Ren, Kai Mao, Weipeng Lan, Jing Lan
{"title":"ENTR1 affects the progression of colon cancer by regulating energy metabolism under the influence of glycolysis.","authors":"Anquan Ma, Chuanyao Zhai, Qixuan He, Wenhao Wang, Huiping Ren, Kai Mao, Weipeng Lan, Jing Lan","doi":"10.1186/s12885-025-14412-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Endosome-associated trafficking regulator 1 (ENTR1), also known as Serologically Defined Colon Cancer Antigen 3 (SDCCAG3), was initially identified in colon cancer and plays a crucial role in protein transport. Preliminary studies indicate that ENTR1 is involved in the growth of certain tumor types.</p><p><strong>Methods: </strong>In this study, we analyzed ENTR1 expression levels in normal and tumor tissues using clinical sample data from multiple databases. We also employed Mendelian randomization (MR) analysis of ENTR1. Finally, we conducted in vitro experiments to validate the effects of ENTR1 on colon cancer proliferation and glycolysis.</p><p><strong>Results: </strong>Our findings reveal that ENTR1 is upregulated in most tumors. Summary-data-based Mendelian Randomization (SMR) analysis indicates a causal relationship between ENTR1 and colon cancer. Further machine learning and metabolite-based Mendelian randomization suggest that ENTR1 may influence tumor growth by regulating glycolysis. Further cellular experiments confirm that knocking out ENTR1 reduces the proliferation of HCT-116 cells and downregulates the expression levels of key glycolytic enzymes.</p><p><strong>Conclusions: </strong>This study uncovers the role of ENTR1 in various cancers and demonstrates that ENTR1 may promote colon cancer growth by regulating glycolysis, providing a new target for cancer therapy.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"992"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135303/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14412-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Endosome-associated trafficking regulator 1 (ENTR1), also known as Serologically Defined Colon Cancer Antigen 3 (SDCCAG3), was initially identified in colon cancer and plays a crucial role in protein transport. Preliminary studies indicate that ENTR1 is involved in the growth of certain tumor types.
Methods: In this study, we analyzed ENTR1 expression levels in normal and tumor tissues using clinical sample data from multiple databases. We also employed Mendelian randomization (MR) analysis of ENTR1. Finally, we conducted in vitro experiments to validate the effects of ENTR1 on colon cancer proliferation and glycolysis.
Results: Our findings reveal that ENTR1 is upregulated in most tumors. Summary-data-based Mendelian Randomization (SMR) analysis indicates a causal relationship between ENTR1 and colon cancer. Further machine learning and metabolite-based Mendelian randomization suggest that ENTR1 may influence tumor growth by regulating glycolysis. Further cellular experiments confirm that knocking out ENTR1 reduces the proliferation of HCT-116 cells and downregulates the expression levels of key glycolytic enzymes.
Conclusions: This study uncovers the role of ENTR1 in various cancers and demonstrates that ENTR1 may promote colon cancer growth by regulating glycolysis, providing a new target for cancer therapy.
期刊介绍:
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.